The growth is being fueled by various factors, chief among them being the huge wave of patent expirations of key branded drugs, which presents opportunities for generic substitutes. Further, the increased global incidence of chronic diseases demands affordable treatment alternatives, further enhancing the market for generics. A crucial regulatory step in bringing generic drugs to market involves demonstrating their bioequivalence to an already approved product known as the Reference Listed Drug (RLD). New generic versions are rigorously compared to the RLD to ensure they perform identically within the body.
This is where Arkon Solutions offers you an indispensable service. Expertizing in the worldwide sourcing and supply of RLDs, Arkon Solutions makes certain that businesses are connected with the necessary products for their bioequivalence testing and regulatory approvals. Taking advantage of a great network of proven suppliers in major regions like EU, USA, Canada, South East Asia, China, and Japan, Arkon Solutions is able to procure pharmaceutical products directly and securely, serving the needs of most major pharmaceutical companies worldwide and streamlining a critical phase of generic drug development.